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In the era of big data, the establishment of a free database, containing all the immune drug 
targets and associated cell types, is of great value. To this aim, the Guide to 
Immunopharmacology has been created in a joint effort between the International Union of 
Basic and Clinical Pharmacology (IUPHAR) and the International Union of Immunological 
Societies (IUIS). Here we highlight the structure and content of the database, which includes 
up-to-date quantitative information on the fundamental science underlying each immune 
target. A set of practical examples and tools for data mining are summarized to support 
immune research into drug discovery and therapeutics. 
 
Article 
Recent and emerging events have highlighted the immense need to link pharmacological and 
immunological research, and accelerate the development of antiviral and immunomodulatory 
drugs. Access to freely accessible databases can strongly contribute to immunology research 
and provide a foundation to scientists and clinicians for developing novel research tolls and 
therapeutics for immune and infectious diseases. 
In this issue of Immunology, we highlight and discuss one of the latest of those database 
resources, the Guide to Immunopharmacology (GtoImmuPdb; 
www.guidetoimmunopharmacology.org).1 The guide has been created, developed and 
maintained by the International Union of Basic and Clinical Pharmacology (IUPHAR) and the 
British Pharmacological Society (BPS), in collaboration with the International Union of 
Immunological Societies (IUIS). The database was initially established with the support of the 
Wellcome Trust. 
This is the first guide specifically designed to cover the pharmacology of the immune system.2-
7 GtoImmuPdb builds on Guide to Pharmacology (GtoPdb, www.guidetopharmacology.org),8 
a long-established dataset containing quantitative information on most of the clinical and 
experimental drug targets and the medications acting on them. 
The GtoImmuPdb is manually curated and constantly updated with support from a broad range 
of class-specific IUPHAR Nomenclature subcommittees, comprising over 500 scientists. To 
date, 618 targets and 1,277 ligands have been included in GtoImmuPdb, based on the 
evidence that their activity has an effect on the immune system and/or the inflammatory 
response. Importantly, the data on targets and ligands have been organized by immunological 
processes, cell types, and disease, with the specific aim to bring valuable and easily 
accessible data into the hands of immunology researchers and clinicians. 
As for any database, data mining may be challenging. For this reason, we are also publishing 
a review article1 that has been specifically designed to help the reader navigate the resource, 
using a straightforward, step-by-step approach, and providing an exemplary case study. For 
each immune-inflammatory ligand or receptor, the reader can access curator comments on 
the association to immune-related disease, details on the drug if approved for clinical use, 
clinical trials, trade names, synonyms, international nonproprietary names (INNs), and tools 
to assess the biological activity and molecular mechanisms. Finally, the case study is 
designed to illustrate the usefulness of GtoImmuPdb to identify novel targets for the treatment 
of vascular inflammation. Similar approaches could be used for the study and identification of 
potential new targets for Covid-19, or any other immune disease/process of interest to the 
readers. It is worth noting that the Guide to Pharmacology has a continually updating list of 
the drugs and targets being proposed or tested for use in Covid-19 
(https://www.guidetopharmacology.org/coronavirus.jsp). 
The GtoImmuPdb may also be used as a very effective educational tool and a medium to 
simplify and standardize immunology-related vocabulary for younger generations, scientists 
and clinicians. In fact, links from key ligands in GtoImmuPdb have now been added to the 
 3 
clinical case studies hosted by Immunopaedia (https://www.immunopaedia.org.za/), the IUIS 
online platform for advancing global immunology education. In a parallel effort, for online 
teaching, the Pharmacology Education Project has been linked to IUIS’ immunopaedia 
(https://www.pharmacologyeducation.org/pharmacology/immunopharmacology). 
In conclusion, Immunology is strongly committed to the development of new therapeutics9-16 
and the provision of educational resources, and therefore we recommend the GtoImmuPdb 
database as a novel tool to accelerate research, education and drug discovery in immunology, 
infection and inflammation. 
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